Rufinamide- Novartis

Drug Profile

Rufinamide- Novartis

Alternative Names: Banzel; CGP 33101; E 2080; Inovelon; RUF 331; SYN 111; Xilep™

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Biotie Therapies Corp.; Eisai Co Ltd
  • Class Antiepileptic drugs; Small molecules; Triazoles
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • No development reported Epilepsy
  • Discontinued Generalised anxiety disorder; Neuropathic pain

Most Recent Events

  • 04 Oct 2017 Rufinamide market licensed to Biotoscana in Latin America
  • 05 Dec 2016 Adverse events data from the pooled analysis in Lennox-Gastaut syndrome released by Esai
  • 05 Dec 2016 Final efficacy data from a phase III trial in Lennox-Gastaut syndrome released by Eisai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top